BSG005 for Systemic Fungal Infections

Biosergen has developed a drug candidate, BSG005, against systemic fungal infections by genetic modification of bacteria that produce antifungal substances. BSG005 has demonstrated good efficacy against Aspergillus and Candida, which cause the two main invasive fungal infections, as well as against many other pathogenic fungi.

Genes for biosynthesis of a polyene macrolide antifungal antibiotic have been cloned and characterized by scientists at NTNU (The Norwegian University of Science and Technology) and SINTEF (Scandinavia’s largest contract research organization), and the complete biosynthetic pathway has been elucidated. It has been demonstrated that novel polyene macrolide analogues can be produced through manipulation of the biosynthetic genes. The gene cluster has been licensed by Biosergen and used, in combination with chemical modifications, to generate a series of new analogues, which have been systematically tested in vitro and in vivo.

Date of article/Start date of trial: 

Thursday, August 11, 2016
New antifungal drugs